Reuters
09 Jun 2026, 01:15 UTC · 3h ago
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports
Search tags
Reuters
09 Jun 2026, 01:15 UTC · 3h ago
Search tags
Story key points
1 claims · impact-rated
GSK is in talks to acquire cancer drugmaker Nuvalent for more than $9 billion. — A multi-billion dollar acquisition indicates strategic growth in oncology and typically drives a premium for the target company's valuation.
+0.60Ticker attribution
Model heads
Company is reportedly being targeted for acquisition at a significant premium of over $9 billion.
Company is expanding its oncology portfolio through a potential strategic acquisition.
Continue reading
6 related stories
[a_to_b] GSK is reportedly in talks to acquire Nuvalent for more than $9 billion.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 10 offered
Seeking Alpha
2h ago
